Hypertension -- Hypertension Instructions to Authors

Instructions to Authors

Hypertension publishes scientific investigation of the highest quality in the broad field of blood pressure regulation and pathophysiology, clinical treatment, and prevention of hypertension. The editors encourage submission of original articles that deal with basic, clinical, and population studies of hypertension and related fields such as nephrology, endocrinology, neuroscience, vascular biology, physiology, pharmacology, cellular and molecular biology, and genetics.

Submitted manuscripts must not contain material previously published, except as an abstract, and must not be under consideration for publication elsewhere, in whole or in part. Manuscripts should conform to "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" (N Engl J Med. 1991; 324:424-428). Manuscripts are examined by the editors and are usually sent to expert reviewers. Decisions will generally be communicated within 3 weeks after receipt of the manuscript. Acceptance is based on originality, scientific excellence, and topical balance of the journal.

Address new and revised manuscripts and correspondence to the editorial office:

John E. Hall, PhD
Hypertension Editor-in-Chief
University of Mississippi Medical Center
2500 N. State St.
Jackson, MS 39216-4505
Phone: 601-815-1667
Fax: 601-815-1675
Email: hypertension{at}physiology.umsmed.edu
Online Submission: http://submit-hyper.ahajournals.org

Editorial Conflict-of-Interest Policy. Original manuscripts authored or coauthored by the Editor in Chief and/or any of the Associate Editors are handled by either a Consulting Editor or an Associate Editor at a different institution, who makes all decisions about the manuscript, (including choice of referees and ultimate acceptance or rejection). The entire process is handled confidentially. All manuscripts submitted from the Editor's home institutions are also handled entirely by either a Consulting Editor or an Associate Editor at a different institution. The Editor in Chief and/or Associate Editors may additionally, from time to time, refer a manuscript to a Consulting Editor to avoid a perceived or real conflict of interest. AHA Scientific Publishing Ethical Conduct Policy

Journal Categories/Article Types	Guidelines for Digital Images
Online Submissions	How to Format Digital Images
General Instructions for Preparing Manuscripts	Online/Data Supplements
Guidelines for Clinical Trials	Costs to Authors
New Manuscripts	Policies
Revised Manuscripts	Forms
Tips for Submitting Online	Permission to Reprint

Journal Categories

Original Scientific Communications. These are regular (original manuscripts) scientific contributions. Manuscripts should not exceed 6000 words including title page, abstract, references, legends, tables, and figures. (Please note that a single bar graph is approximately 150 words, and table with 3 columns and 10 rows is approximately 100 words.) In exceptional circumstances, the editors may consider manuscripts longer than 6000 words when design complexity or research requires a greater length. For preparation, see "General Instructions."

Brief Reviews. Brief Reviews are generally invited by the Editors and are definitive summaries of areas that are important to research in hypertension and related areas. Reviews should briefly, but comprehensively, review the literature on a specified topic. The topic should be timely and sufficiently focused to allow a comprehensive review without exceeding 6000 words, including title page, abstract, references, legends, and tables, and figures. (Please note that a single bar graph is approximately 150 words, and table with 3 columns and 10 rows is approximately 100 words.) In special circumstances, reviews may exceed these page limits and specific guidelines will be provided at the time that the review is invited. The author should discuss controversies that have been resolved or that remain, the future of the field both technically and conceptually, and define major unresolved questions. All Brief Reviews, whether invited or not, will undergo peer review.

Hypertension Grand Rounds. These articles are invited reviews that take a case-based approach, including topics related to diagnosis, prevention, and treatment of hypertension. The case presentation will be followed by a discussion of scientific and practical clinical issues related to the case. Where applicable, a discussion of future research necessary for resolving unanswered questions will be included. The topic should be timely and sufficiently focused to allow a comprehensive review without exceeding 6000 words, including title page, case presentation, references, legends, tables, and figures . (Please note that a single bar graph is approximately 150 words, and table with 3 columns and 10 rows is approximately 100 words.) In special circumstances, reviews may exceed these page limits and specific guidelines will be provided at the time that the review is invited. Hypertension Grand Rounds, whether invited or not, will undergo peer review.

Hypertension Highlights. These articles are intended to highlight, provide further perspective, and enhance the overall significance of recent studies published in Hypertension that contribute to our understanding of hypertension and related areas. Hypertension Highlights should be approximately 3000 words and review progress that has occurred during the past 2-3 years in a focused area of hypertension research. Figures that effectively illustrate and summarize key points are encouraged. References should generally be restricted to those published in Hypertension during the last 2-3 years.

Editorial Commentaries. These articles are invited brief commentaries on articles that appear in Hypertension or on topics of particular importance to the readers of the journal. They should be approximately 1500 words, describe controversial issues, and review questions that remain to be addressed. Use of a figure to illustrate key points is encouraged. References are limited to 10 and generally should be restricted to recent years. Editorial Commentaries are generally invited by the editors, but whether invited or not, they will undergo peer review.

Tutorials. These are similar to Brief Reviews but are presented at a level commensurate with their use as a teaching tool. Schematic diagrams and figures are encouraged wherever possible to illustrate important scientific or technical points. Elements of Editorial Commentaries can also be integrated into the tutorial at the author's discretion. The topic should be timely and sufficiently focused to allow a comprehensive review without exceeding 6000 words, including title page, abstract, references, legends, and tables, and figures. (Please note that a single bar graph is approximately 150 words, and table with 3 columns and 10 rows is approximately 100 words.) In special circumstances, Tutorials may exceed these page limits and specific guidelines will be provided at the time that the review is invited. The author should discuss controversies that have been resolved or that remain, the future of the field both technically and conceptually, and define major unresolved questions. Tutorials, whether invited or not, will undergo peer review.

Letters to the Editor. Letters to the Editor express views about articles published in Hypertension. Letters should be no longer than 500 words and should relate to an article published in Hypertension, within the preceding three months. References are limited to 5. Authors of the article cited in the letter will be invited to reply, as appropriate, and the reply must be signed by all authors of the original publication.

Preliminary or circumscribed novel findings of unusual interest may also be submitted as a Letter to the Editor and should be no longer than 1000 words. Authors must double-space text and references, provide a brief title, and obtain signatures from all authors on a copyright transfer agreement for all Letters to the Editor. Letters and replies are reviewed by the Editors and may be edited, and they will appear online only.

[Top]

Manuscript Submissions

Online Submissions: A formal online submission module is available and is the preferred mode of submission to Hypertension. To submit your original or revised manuscript online, please go to http://submit-hyper.ahajournals.org and follow the detailed instructions located on our submission website. If you have any questions about the online submission process, please feel free to contact the Editorial Office at hypertension{at}physiology.usmed.edu. If you do not receive confirmation of submission within three days, please contact the Editorial Office. The following items should be uploaded at the time of submission:

A cover letter that includes a statement of submission: "All authors have read and approved the submission of the manuscript; the manuscript has not been published and is not being considered for publication elsewhere, in whole or in part, in any language, except as an abstract." The cover letter may include the names of six to eight potential reviewers, with address, email address, and fax number, who are experts in the area of research and who do not have a conflict of interest. It is especially helpful to suggest three to four members of the Editorial Board.
Authorship Responsibility and Copyright Transfer Agreement
Acknowledgment release signatures, if applicable
One copy of any potentially overlapping work that is in preparation, has been previously submitted or published, or is in-press, if applicable
One copy of any article currently in-press, which is cited in the References, if applicable
One copy of any abstracts published or submitted for publication, if applicable
All sources of support must be cited
All potential conflicts of interest related to the manuscript must be stated Conflict of Interest Disclosure Questionnaire

If you are unable to upload the items above, please fax them to the Hypertension Editorial Office within 48 hours after completion of online manuscript submission.

[Top]

General Instructions for New Submissions

Manuscripts must be typed, double-spaced using a 12-point font, including references, figure legends, and tables, on one side of the page only.

Leave 1-inch margins on all sides. Do not use proportional spacing or justified margins.

Number every page except the title page, including figures, tables, and references. Cite each figure and table in text in numerical order.

Assemble manuscripts in this order:

Title page
Abstract
Text, including Introduction, Methods, Results, Discussion, and Perspectives
Acknowledgments
Source(s) of Funding
Conflict(s) of Interest/Disclosure(s)
References
Figure Legends
Tables
Figures

Cite each reference in text in numerical order and list in the References section. In-text reference numbers may be repeated but not omitted.

Use SI units of measure in all manuscripts. For example, molar (M) should be changed to mol/L; mg/dL to mmol/L; and cm to mm. Units of measure previously reported as percentages (ie, hematocrit) are expressed as a decimal fraction. Measurements currently not converted to SI units in biomedical applications are blood and oxygen pressures, enzyme activity, H+ concentration, temperature, and volume. The SI unit should be used in text, followed by the conventionally used measurement in parentheses.

For style, consult the , Baltimore, MD, Williams & Wilkins, 1998. (NOTE: The use of et al. in the author listing of references is not allowed.)
Please provide sex-specific and/or racial/ethnic-specific data, when appropriate, in describing outcomes of epidemiologic analyses or clinical trials; or specifically state that no sex-based or racial/ethnic-based differences were present. See the Uniform Requirements for more details.
Consult current issues of Hypertension for examples of format.

[Top]

Guidelines for Clinical Trials

In accordance with the Clinical Trial Registration Statement from the International Committee of Medical Journal Editors (ICMJE) (Circulation. 2005;111:1337-1338.), all clinical trials submitted for publication in Hypertension must be registered in a public trials registry at or before the onset of participant enrollment. This requirement applies to all clinical trials that begin enrollment after July 1, 2005.
Research is considered to be a clinical trial if it involves prospective assignment of human subjects to an intervention or comparison group to study the relation between a medical intervention and a health outcome. Studies that are designed for other purposes, such as to study pharmacokinetics or major toxicity studies (e.g., phase 1 trials) are exempt.
The registry must be accessible to the public at no charge, searchable, open to all prospective registrants, and managed by a not-for-profit organization. The registry must include the following information: a unique identifying number, a statement of the intervention(s), study hypothesis, definition of primary and secondary outcome measurements, eligibility criteria, target number of subjects, funding source, contact information for the principal investigator, and key dates (registration date, start date, and completion date). The registries listed below are approved by the ICMJE:
Clinical trials maybe listed with Other registries, but these registries must meet the above-mentioned requirements.
The authors will be requested to provide the exact URL and unique identification number for the trial registration at the time of submission. This information will be published in a footnote on the first page of the article.
Clinical trial reports should also comply with the Consolidated Standards of Reporting Trials (CONSORT) and include a flow diagram presenting the enrollment, intervention allocation, follow-up, and data analysis with number of subjects for each. Please also refer specifically to the CONSORT Checklist of items to include when reporting a randomized clinical trial.
[Top]
General Instructions for Revised Manuscripts
- In the top right-hand corner, indicate the manuscript number followed by R1 to denote a first revision.
- In your written response to the reviewers' comments, give the page number(s), paragraph(s), and line number(s) where each revision was made.
- Revisions not received within three months will be administratively withdrawn. For further consideration the manuscript must be resubmitted de novo. At the editors' discretion, and in cases where substantial new data are required, extensions may be granted for revisions. In such cases, every effort will be made to retain the original reviewers.
- Respond to each referee's comments, indicating precisely the changes made in response to the critiques. Also give reasons for suggested changes that were not implemented, and identify additional changes made.
[Top]

General Instructions for Preparing a Manuscript
1. Text
  Abbreviations. Abbreviations should be defined at the first mention in the text.
  Methods section. The methods section should provide sufficient detail for the experiments to be reproduced.
  
  Materials and Data Availability: To allow others to replicate and build on work published in Hypertension, authors should make materials, data, and associated protocols available to readers or list the primary source of materials. Authors must disclose upon submission of the manuscript any restrictions on the availability of materials or information.
  Authors should make Unique Materials (e.g., cloned DNAs; antibodies; bacterial or animal cells; viruses; and computer programs) promptly available on request by qualified researchers for their own use. It is reasonable for authors to charge a modest amount to cover the cost of preparing and shipping the requested material and some materials may require a Materials Transfer Agreement between institutions.
  
  Studies in Experimental Animals: Indicate that the study was approved by an institutional review committee. All studies in animals should be conducted in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals, or the equivalent. The species, strain, number used, and other relevant characteristics of the animals should be stated. When describing surgical procedures, identify the pre-anesthetic and anesthetic agents used and state the amount or concentration and the route and frequency of administration for each. The use of paralytic agents, such as curare or succinylcholine, is not an acceptable substitute for anesthetics. For other invasive procedures, report the analgesic or tranquilizing drugs used. If none was used, provide justification for such exclusion. Generic names of drugs must be given.
  
  Studies in Humans: Indicate that the study was approved by an institutional review committee and that the subjects gave informed consent. All studies that involve the use of humans must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, Revised November 13, 2001, effective December 13, 2001. Describe the characteristics of human subjects or patients and indicate that the procedures followed were in accordance with institutional guidelines.
  
  Blood Pressure Methods for Human Studies: Blood pressure measurement methods should be described in detail in the text or by reference. Information should include number of readings, instrument type(s), cuff size(s), arm position, posture, and observer training.
  
  Genomic and Proteomic Studies: All papers reporting gene expression profiling data must comply with the Minimum Information About Microarray Data Experiments (MIAME) standard. Authors of papers that include genomic, proteomic, or other high-throughput data are required to make their data easily accessible for the reviewers and the editors during the review process. You may submit your data to the NCBI gene expression and hybridization array data repository (GEO) and provide the GEO accession number, or you may provide a link to a secure or publicly accessible website which hosts the data. Prior to publication, the data must be submitted and an accession number obtained. Access to the information in the database must be available at the time of publication. GEO has a web-based submission route, suitable for a small number of samples, or a batch submission tool (called SOFT). Submission FAQ.
  
  Guidelines for Protein and Nucleic Acid Sequences: Newly reported nucleotide or protein sequences must be deposited in GenBank or EMBL databases, and an accession number must be obtained. Access to the information in the database must be available at the time of publication. Authors are responsible for arranging release of data at the time of publication. The authors must also provide a statement in the manuscript that this sequence has been scanned against the database and all sequences with significant relatedness to the new sequence identified (and their accession numbers included in the text of the manuscript).
  GenBank
  GenBank Submissions, National Center for Biotechnology Information, 8600 Rockville Pike, Building 38A, Room 8N-805, Bethesda, MD 20894, Tel: (301) 496-2475
  
  EMBL Nucleotide Sequence Submissions
  European Bioinformatics Institute, Hinxton Hall, Hinxton, Cambridge CB10 1SD, UK, Tel.: 44-1223-494401; Fax: 44-1223-494472; e-mail: support@ebi.ac.uk
  
  DNA Data Bank of Japan
  Center for Information Biology, National Institute of Genetics, Mishima, Shizuoka, 411, Japan, Tel.: 81-559-81-6853; Fax: 81-559-81-6849
  Submission to any data bank is sufficient to ensure entry in all.
  
  Guidelines for Human Phenotype-Genotype Association or Linkage Studies:
  
  Reporting issues.
  
  Report process for selecting genes and SNPs.
  
  Report Hardy-Weinberg statistics or p-values and method of calculating same.
  
  Refer to existing public domain websites for the Human Gene Ontology name and the rs number for SNPs.
  
  http://www.gene.ucl.ac.uk/nomenclature
  
  http://www.ncbi.nlm.nih.gov/projects/SNP
  
  http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Snp
  
  Describe genotyping methods. If numerous primers have been used, please include them in an online supplement.
  
  False positive and false negative concerns. Given well-described problems with both false positive and false negative associations, phenotype-genotype association studies should meet some or all of the criteria below:
  
  Phenotype is clearly defined, is heritable, and if a quantitative phenotype is reported, reproducibility data are provided or referenced.
  
  The sample size is adequate to detect a SNP or haplotype with a modest effect. For genotype-trait associations, provide an estimate of the effect size that could be detected with power 0.80 or higher with the allele frequency and sample size reported.
  
  Since multiple statistical testing methods are frequently used in genotyping-phenotyping studies, please include specifics of the primary model(s) tested. Non-essential secondary models may be published as electronic data supplements. Clinically relevant confounders should be included in multivariable models or residuals.
  
  Review criteria for human linkage studies. Manuscripts should include the following:
  
  Identifying plausible candidate genes under the linkage peak.
  
  Follow-up fine mapping to narrow the region of linkage, and/or genotyping some of the candidate genes under the linkage peak.
  
  Replication data from another sample.
  
  Guidelines for Studies on Diagnostic Tests: For information regarding the Standards for Reporting of Diagnostic Accuracy (STARD) go to Clinical Chemistry.2003;49:7-18. or Ann of Intern Med. 2003;138:W1-W12.
  
  Drugs and Reagents: Give generic rather than trademark names of drugs. The generic chemical identification of all investigational drugs must be provided. The complete name and location of the manufacturer must be supplied for all reagents, equipment, and devices used in the Methods.
  
  Statistics: A subsection on statistics should be included in the Methods section and the measures of variance, such as standard deviation or standard error, should be indicated.
  
  Methods should be limited to essential new information. To save space for the authors and the journal, if methods have been previously published, the author may refer to that paper and submit copies of that paper as reference material.
  
  The following information should be included as an Online Data Supplement:
  
  For animals used in experiments, state the species, strain, number used, and other pertinent descriptive characteristics.
  
  For human subjects or patients, describe their characteristics.
  
  When describing surgical procedures on animals, identify the pre-anesthetic and anesthetic agents used and state the amount or concentration and the route and frequency of administration for each. The use of paralytic agents, such as curare or succinylcholine, is not an acceptable substitute for anesthetics. For other invasive procedures on animals, report the analgesic or tranquilizing drugs used. If none was used, provide justification for such exclusion. Generic names of drugs must be given.
  
  Manuscripts that describe studies on humans must indicate that the study was approved by an institutional review committee and that the subjects gave informed consent. Reports of studies on both animals and humans must indicate that the procedures followed were in accordance with institutional guidelines. To save space for the authors and the journal, if methods have been previously published, the author may refer to that paper and submit copies of that paper as reference material.
  
  Discussion. This section should not be used to restate the results but rather to illuminate and place into perspective the results. Excessive discussion and reiteration of points that are obvious from the results are discouraged.
  
  "Perspectives". Authors should include a brief (<250) "Perspectives" section at the end of the Discussion Section. The "Perspectives" section should be clearly labeled with a separate heading. The purpose of "Perspectives" is to indicate the broad implications of the study, and to permit reasonable speculation on the overall importance and future directions of the work. Such perspectives should not replace the conclusions drawn from the study and should be limited to one paragraph. This section should, however, replace the "In summary..." paragraph that is often placed at the end of the discussion.
2. Acknowledgments
  The Acknowledgments section lists substantive contributions of individuals. The Editorial Office must receive written, signed consent from each person recognized in the Acknowledgments to be mentioned in the article, because acknowledgment can imply endorsement of data and conclusions.
3. Sources of Funding
  Authors must list all sources of support for research in this section.
4. Conflict(s) of Interest/Disclosure(s) Statement
  Authors must disclose any and all relationships that could be perceived as real or apparent conflict(s) of interest as a FOOTNOTE after the Sources of Funding section. Conflict-of-interest/disclosure will be published as a footnote to the accepted article. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the article. Such relationships include, but are not limited to, employment by an industrial concern, ownership of stock, membership on a standing advisory council or committee, being on the board of directors, or being publicly associated with the company or its products. Other areas of real or perceived conflict of interest related to the subject of the article could include receiving honoraria or consulting fees or receiving grants or funds from such corporations or individuals representing such corporations.
  If no author has anything to disclose, please list "None".
5. References
  - References must conform to the journal's style -- consult the American Medical Association Manual of Style, 9th ed, Baltimore, MD, Williams & Wilkins, 1998.(NOTE: All authors must be listed in the author listing.)
  - Accuracy of reference data is the author's responsibility. Verify all entries against original sources, especially journal titles, inclusive page numbers, publication dates, accents, diacritical marks, and spelling in languages other than English.
  - All references must be double-spaced.
  - All authors must be listed in references. Shortened lists of author names followed by "et al" must be replaced with complete information.
  - Cite references in numerical order according to first mention in text.
  - Personal communications, unpublished observations, and submitted manuscripts must be cited in the text as "(authors' full names, unpublished data, year)."
  - Abstracts may be cited only if they are the sole source and must be identified in the reference as "Abstract."
  - "In press" citations must have been accepted for publication and the name of the journal or book publisher included.
6. Tables
  - Each table must begin on a separate page, double-spaced. The table number must be in Arabic numerals followed by a period and a brief informative title.
  - Use same size type as in text.
  - Supply a brief heading for each column.
  - Indicate footnotes in tables by symbols in this order: *, �, �, �, ||, �, #, **.
  - Do not use vertical lines in tables. Use horizontal lines above and below the column headings and at the bottom of the table only. Use extra space to delineate sections within the table.
  - Do not duplicate data in figures and tables.
  - Define acronyms and abbreviations in a separate listing.
  (Please note that a table with 3 columns and 10 rows is approximately 100 words.)
7. Figures and Legends
  - Figures may be black and white line drawings, graphs, color illustrations, or halftones (gel blots/stains).
  - Authors are responsible for the cost of printing color illustrations.
  - Flaws will not be corrected.
  - Figure parts should be clearly labeled. Letters, symbols, arrows, etc must be uniform in size and style within each figure, and when possible between figures. We recommend that you use either 12 pt Arial Bold font or 14 pt Times New Roman Bold font.
  - Avoid headings on the figure when possible. Heading information should appear in the figure legend.
  - Line art should not contain very thin lines, which are hard to reproduce.
  - Supply a scale bar with photomicrographs.
  - Provide figure legends on a separate page, double-spaced.
  - If there are abbreviations or symbols in the figures, they must be defined in the figure or the figure legend.
  - Limit white space between all panels and between panels and panel labels.
  - Electronic source files of figures may be submitted in a pdf format for initial submission of a manuscript. Electronic source files of figures for subsequent submissions must follow the guidelines set by the publishers.
  - Guidelines for digital images
    The use of digital media for image acquisition and processing introduces the potential for inadvertent distortion of data. To prevent such distortion, the following guiding principles should be used:
    1. Data should neither be added to, nor removed from, an image by digital manipulation. Images gathered at different times or from different locations should not be combined into a single image, unless it is stated that the resultant image is a product of time-averaged data or a time-lapse sequence. Figures assembled from multiple images must indicate the separation of the parts by lines and described in the legend.
    2. The use of touch-up tools, such as cloning and healing tools in Photoshop, or any feature that deliberately obscures manipulations, is unacceptable.
    3. Linear adjustment of contrast, brightness or color must be applied equally to controls and all parts of an entire image. Contrast should not be adjusted so that data disappear. Excessive manipulations, such as processing to emphasize one region in the image at the expense of others (e.g. through the use of a biased choice of threshold settings), is unacceptable, as is emphasizing experimental data relative to the control.
    4. When submitting revised final figures upon conditional acceptance, authors may be asked to submit original, unprocessed images.
    5. All image acquisition tools and image processing software packages used should be listed. Deviations from the above, including nonlinear adjustments, must be indicated in the figure legend along with a description of the processing software used.
  - How to format digital images is available at Instructions on Formatting Digital Images
  - If you are unable to size your digital art appropriately or provide the correct resolution, we encourage you to send a PDF created from the original source file of the figure (i.e. In the program that created the figure, 1) go to your print menu, 2) change printer to Adobe PDF, and 3) save file as the MS #-Fig 1, etc.).
  (Please note that a single bar graph is approximately 150 words.)
8. Cover Figures
  The editors encourage submission of color images for consideration as potential cover figures. These may be uploaded along with a figure legend as a supplemental file when a revised manuscript is submitted. Please make sure to clearly label this as a cover figure.
  - Cover figures should illustrate a major finding or concept and be associated with the general topic of the article, or they may be altered/enhanced versions of an original figure within the manuscript.
  - A photograph or diagram is appropriate, but complex flow charts are not suitable.
  - A very brief caption should be included.
  - Cover figure submissions must follow the same guidelines as original figure submissions attached to manuscripts (see "Figures and Legends").
  [Top]
9. Online Supplements
  This optional section provides an opportunity for authors to present supporting materials to the manuscript. The manuscript appears both in the print version and online, whereas Online Supplements are independent from the manuscript and appear only online. Online Supplements undergo peer review and therefore must be submitted simultaneously with original submissions.
  Online Supplements may consist of any of the following, in any combination: the expanded materials and methods; additional figures and supporting information; additional tables and supporting information; and, video files.
  The guidelines below should be used for online supplements:
  - Material to be published as an online only supplement should be uploaded online as either a word doc or pdf, if possible. An exception to this would be if the online supplement is a video file.
  - The online supplement should have a title page with the label of ONLINE SUPPLEMENT above the title.
  - The online supplement should be single-spaced.
  - If citations are made in the Online Supplement, the Online Supplement must contain its own independent Reference Section with references numbered sequentially, beginning with reference 1, even if some of these references duplicate those in the print version.
  - Number supplementary figures and tables as S1, S2, etc.
  - Place the supplemental figure legend underneath the corresponding figure.
  - When referring to online-only material in the print version of the manuscript, use the phrase "please see http://hyper.ahajournals.org."
  Data Supplements appear only online and will not appear in reprints of the article. The Editorial Office is not responsible for converting files to a suitable format.
  The print version of the Table of Contents of Hypertension highlights articles that contain Online Supplements by having "Data Supplement Online" typed in a box underneath the author listing.
  [Top]
10. Deposits of Manuscripts to Repositories such as PubMed Central
  - All rights, title, interest and copyright ownership in a manuscript submitted to the American Heart Association is conveyed by the author(s) to the American Heart Association. If a manuscript is supported in whole or part by a funding body, such as the NIH, then authors are authorized to deposit the manuscript in the funding body�s designated repository but must specify that it be made public no later than 6 months after publication in Hypertension.
  - As of May 2, 2005, the NIH has requested that manuscripts funded in whole or part by NIH funds be deposited in PubMedCentral (PMC). The manuscript to be deposited is the �preprint� form of the manuscript.
  - For more information about author�s rights and responsibilities, please see the AHA Authorship Responsibility and Copyright Transfer Agreement.
  - For more information on PubMedCentral please visit http://nihms.nih.gov.
  - A Permissions and Rights Question and Answer is also available (http://www.ahajournals.org/rights/).
  [Top]
  
  Permissions
  Address requests for permission to reproduce figures, tables, or portions of articles originally published in Hypertension to: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters Kluwer Health, 351 West Camden Street, Baltimore, MD 21201-2436.
  Include two copies of the request and a self-addressed, stamped envelope. Phone: 410-528-4050; fax: 410-528-8550; E-mail: journalpermissions@lww.com.
  
  [Top]
  Costs to Authors
  Authors are charged:
  1. $70 per printed page of an article to defray costs of publication (information is sent with author's proof) or $35 per page in the case of copyedited online-only material.
    Authors of papers that are accepted for publication and that exceed the 6,000 word limit will be charged for the overage. Authors will be charged an additional $425 for each additional 1,000 words over 6,000. The usual $70 page charge will also apply. Word count will be calculated by the editorial office and will include references, figures, and tables.
  2. Expense for color reproduction of figures are based on the number of figures. Charges are $495 for 1 figure, $990 for 2, $1350 for 3, and $1710 for 4. Each additional figure after 4 color figures is $90. Color figures that are online only are half the print cost.
  3. Expense for replacing poor-quality art
  4. Expense for reprints (price lists are sent with the author's proof)
  5. $50 per printed page for excessive author alterations
  6. $100 per page for printing a correction (erratum) resulting from an author's error, after publication of the article
  [Top]
  
  Policies
  AHA Scientific Publishing Conflict of Interest Policy
  AHA Scientific Publishing Ethical Conduct Policy
  
  [Top]
  
  Forms
  Authorship Responsibility and Copyright Transfer Agreement
  Conflict(s) of Interest/Disclosure(s) Questionnaire
  Acknowledgment Permission Form
  Change of Authorship Form
  
  [Top]
  
  Artwork Guidelines (PDF)
  Journal Subject Heads for Article Collections Feature on Journals Web Site
  Key Word List
  Journal Permissions (PDF)